pubmed-article:16114285 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:16114285 | lifeskim:mentions | umls-concept:C0027793 | lld:lifeskim |
pubmed-article:16114285 | lifeskim:mentions | umls-concept:C0282151 | lld:lifeskim |
pubmed-article:16114285 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
pubmed-article:16114285 | lifeskim:mentions | umls-concept:C2698651 | lld:lifeskim |
pubmed-article:16114285 | pubmed:issue | 31 | lld:pubmed |
pubmed-article:16114285 | pubmed:dateCreated | 2005-8-23 | lld:pubmed |
pubmed-article:16114285 | pubmed:abstractText | Dopaminergic neurotransmission affects an individual's subjective experience. Individuals with lower baseline dopamine function are at an increased risk for dysphoric responses during antipsychotic therapy with dopaminergic-blocking drugs. Reaching an optimal dopamine D2-receptor occupancy is therefore relevant for the quality of life. Doses of antipsychotic drugs administered to such individuals often need to be lower than the commonly used levels, as these may induce drowsiness and lack of energy. | lld:pubmed |
pubmed-article:16114285 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16114285 | pubmed:language | dut | lld:pubmed |
pubmed-article:16114285 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16114285 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:16114285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16114285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16114285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16114285 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:16114285 | pubmed:month | Jul | lld:pubmed |
pubmed-article:16114285 | pubmed:issn | 0028-2162 | lld:pubmed |
pubmed-article:16114285 | pubmed:author | pubmed-author:de HaasCC | lld:pubmed |
pubmed-article:16114285 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:16114285 | pubmed:day | 30 | lld:pubmed |
pubmed-article:16114285 | pubmed:volume | 149 | lld:pubmed |
pubmed-article:16114285 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:16114285 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:16114285 | pubmed:pagination | 1721-2 | lld:pubmed |
pubmed-article:16114285 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:16114285 | pubmed:meshHeading | pubmed-meshheading:16114285... | lld:pubmed |
pubmed-article:16114285 | pubmed:meshHeading | pubmed-meshheading:16114285... | lld:pubmed |
pubmed-article:16114285 | pubmed:meshHeading | pubmed-meshheading:16114285... | lld:pubmed |
pubmed-article:16114285 | pubmed:meshHeading | pubmed-meshheading:16114285... | lld:pubmed |
pubmed-article:16114285 | pubmed:meshHeading | pubmed-meshheading:16114285... | lld:pubmed |
pubmed-article:16114285 | pubmed:meshHeading | pubmed-meshheading:16114285... | lld:pubmed |
pubmed-article:16114285 | pubmed:meshHeading | pubmed-meshheading:16114285... | lld:pubmed |
pubmed-article:16114285 | pubmed:meshHeading | pubmed-meshheading:16114285... | lld:pubmed |
pubmed-article:16114285 | pubmed:meshHeading | pubmed-meshheading:16114285... | lld:pubmed |
pubmed-article:16114285 | pubmed:meshHeading | pubmed-meshheading:16114285... | lld:pubmed |
pubmed-article:16114285 | pubmed:year | 2005 | lld:pubmed |
pubmed-article:16114285 | pubmed:articleTitle | [The optimal level of dopaminergic neurotransmission]. | lld:pubmed |
pubmed-article:16114285 | pubmed:affiliation | Academisch Medisch Centrum/Universiteit van Amsterdam, locatie MFO Psychiatrie/AMC De Meren, Adolescentenkliniek, Tafelbergweg 25, 1105 BC Amsterdam. l.dehaan@amc.uva.nl | lld:pubmed |
pubmed-article:16114285 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:16114285 | pubmed:publicationType | English Abstract | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16114285 | lld:pubmed |